Spherix to start phase 3 trial of Naturlose for diabetes

New York, Dec. 6 - Spherix Inc. said it plans to start a phase 3 clinical trial of Naturlose for type 2 diabetes.

The news follows a meeting with the Food and Drug Administration that reviewed pharmacological, toxicological and efficacy data from phase 1 and 2 trials and found Naturlose to be qualified for phase 3.

Spherix said it is now selecting a contract research organization to carry out the phase 3 trial.

Spherix is a Beltsville, Md., technology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.